Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase Ib/II, Open-Label Study Of PF-07901801 In Combination with Glofitamab After a Fixed, Single Dose of Obinutuzumab in Participants with Relapsed/Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplantation
Study Type: Treatment
Phase: I/II
NCTID: NCT05896163
Principal Investigator:
Marc Hoffmann
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy
Study Type: Other
Phase: N/A
NCTID: NCT02445222
Principal Investigator:
Gary Myers
A Phase I/II, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogenic Anti-CD7 Car-T Cells BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia T-ALL or T-Cell Lymphoblastic Lymphoma T-LL
Study Type: Treatment
Phase: I/II
NCTID: NCT05885464
Principal Investigator:
Forat Lutfi
A Randomized Phase II study of Brentuximab Vedotin NSC 749710 and Crizotinib NSC 749005 in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma ALCL IND 117117
Study Type: Treatment
Phase: II
NCTID: NCT01979536
Principal Investigator:
An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib RP6530, a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase HDAC inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Study Type: Treatment
Phase: II
NCTID: NCT05633615
Principal Investigator:
Marc Hoffmann
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Study Type: Treatment
Phase: III
NCTID: NCT03267433
Principal Investigator:
Nausheen Ahmed
An Adaptive Phase III, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Treatment as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Study Type: Treatment
Phase: III
NCTID: NCT05605899
Principal Investigator:
Nausheen Ahmed